|
1
|
A randomized trial of Ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease.
|
Gastroenterology
|
2008
|
3.36
|
|
2
|
Infliximab maintenance treatment reduces hospitalizations, surgeries, and procedures in fistulizing Crohn's disease.
|
Gastroenterology
|
2005
|
2.05
|
|
3
|
Long-term infliximab maintenance therapy for ulcerative colitis: the ACT-1 and -2 extension studies.
|
Inflamm Bowel Dis
|
2011
|
1.22
|
|
4
|
A pooled analysis of infections, malignancy, and mortality in infliximab- and immunomodulator-treated adult patients with inflammatory bowel disease.
|
Am J Gastroenterol
|
2012
|
1.22
|
|
5
|
Pharmacokinetic properties of infliximab in children and adults with Crohn's disease: a retrospective analysis of data from 2 phase III clinical trials.
|
Clin Ther
|
2011
|
1.11
|
|
6
|
O-001 A Multicenter, Double-Blind, Placebo-Controlled Phase3 Study of Ustekinumab, a Human IL-12/23P40 mAB, in Moderate-Service Crohn's Disease Refractory to Anti-TFNα: UNITI-1.
|
Inflamm Bowel Dis
|
2016
|
1.01
|
|
7
|
Induction and maintenance therapy with infliximab for children with moderate to severe ulcerative colitis.
|
Clin Gastroenterol Hepatol
|
2011
|
1.00
|
|
8
|
Ustekinumab: lessons learned from targeting interleukin-12/23p40 in immune-mediated diseases.
|
Ann N Y Acad Sci
|
2009
|
0.97
|
|
9
|
Relationship of C-reactive protein with clinical response after therapy with ustekinumab in Crohn's disease.
|
Am J Gastroenterol
|
2009
|
0.96
|
|
10
|
Endoscopic and clinical variables that predict sustained remission in children with ulcerative colitis treated with infliximab.
|
Clin Gastroenterol Hepatol
|
2013
|
0.86
|
|
11
|
Pharmacokinetics of infliximab in children with moderate-to-severe ulcerative colitis: results from a randomized, multicenter, open-label, phase 3 study.
|
Inflamm Bowel Dis
|
2013
|
0.81
|
|
12
|
Safety and efficacy of maintenance infliximab therapy for moderate-to-severe Crohn's disease in children: REACH open-label extension.
|
Curr Med Res Opin
|
2011
|
0.80
|